Other N-Methyl-D-Aspartate (NMDA) Receptor Antagonists with a Rapid Onset of Action and Less Side Effect in the Treatment of Depression
Journal of the Korean Society of Biological Psychiatry
;
: 149-154, 2015.
Artículo
en Coreano
| WPRIM
| ID: wpr-725356
ABSTRACT
Mood disorder is a common psychiatric illness with a high lifetime prevalence in the general population. Many prescribed antidepressants modulate monoamine neurotransmitters including serotonin, norepinephrine and dopamine. There has been greater focus on the major excitatory neurotransmitter in the human brain, glutamate, in the pathophysiology and treatment of major depressive disorder (MDD). Recently, ketamine, an N-methyl-D-aspartate receptor antagonist, has received attention and has been investigated for clinical trials and neurobiological studies. In this article, we will review the clinical evidence for glutamatergic dysfunction in MDD, the progress with ketamine as a rapidly acting antidepressant, and other N-methyl-D-aspartate receptor antagonist for treatment-resistant depression.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Encéfalo
/
Dopamina
/
Serotonina
/
Norepinefrina
/
Prevalencia
/
N-Metilaspartato
/
Neurotransmisores
/
Ácido Glutámico
/
Trastornos del Humor
/
Depresión
Tipo de estudio:
Estudio de prevalencia
Límite:
Humanos
Idioma:
Coreano
Revista:
Journal of the Korean Society of Biological Psychiatry
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS